胰腺癌患者血清可溶性Apo-1/Fas水平变化及其临床意义

目的探讨胰腺癌患者血清可溶性Apo1/Fas(sApo1/Fas)水平的变化,以及化疗对血清sApo1/Fas的影响。方法采用酶联免疫吸附试验(ELISA)检测并比较58例胰腺癌患者和30例正常人的血清sApo1/Fas水平,比较48例胰腺癌患者化疗前后血清sApo1/Fas水平。结果胰腺癌患者血清sApo1/Fas为(8.37±1.49)ng/L,明显高于正常对照组(P<0.01)。胰腺癌患者血清sApo1/Fas水平与临床分期有关,Ⅳ期胰腺癌血清sApo1/Fas水平明显高于其他各期(P<0.01),Ⅲ期明显高于Ⅱ期(P<0.01);与胰腺癌患者的性别、年龄、病理类型无关。近期有效(完全缓解和部分缓解)的患者化疗前后血清sApo1/Fas分别为(8.07±1.54)ng/L和(7.39±1.49)ng/L,化疗后血清sApo1/Fas水平低于化疗前(P<0.01)。结论血清sApo1/Fas水平可能与胰腺癌的病情发展有关,血清sApo1/Fas检测对胰腺癌的疗效观察、病情监测及预后判断有重要的参考意义。

Changes and clinical significance of serum soluble Apo-1/Fas in pancreatic cancer

OBJECTIVE: To detect changes of serum soluble Apo-1/Fas (sApo-1/Fas) in pancreatic cancer patients and to investigate its clinical value in assessing the effect of chemotherapy. METHODS: The serum level of sApo-1/Fas in 30 normal control subjects and 58 pancreatic cancer patients were detected using enzyme-linked immunosorbent assay (ELISA), and the sApo-1/Fas level of 48 pancreatic cancer patients, before and after chemotherapy was compared. RESULTS: Compared with the level of the control group, the level of serum soluble Apo-1/Fas was significantly correlated with clinical stage but not with age, sex or pathologic type of pancreatic cancer. It was elevated gradually from stage II to IV (P < 0.01). However, it would obviously decrease in pancreatic cancer patients after chemotherapy (P < 0.01). CONCLUSION: The serum soluble Apo-1/Fas may be involved in the development of pancreatic cancer, and it may be used as one parameter to assess the disease status and prognosis of pancreatic cancer patient.